Site navigation

Navigation

Diabetes (type 2) - glitazones (replaced by CG66)

Glitazones in the treatment of type 2 diabetes (Review of TA9 and TA21)

Summary

The recommendations in this technology appraisal have been replaced by recommendations in the type 2 diabetes clinical guideline published in May 2008. Therefore this guidance is obsolete.


Guidance documents

  • No documents found

Implementing this guidance

  • None available

Other information

About this guidance

Technology appraisals TA63

Issued: August 2003

How this guidance was produced

See also:

See this guidance in practice:

Order printed copies of this guidance